Less Ads, More Data, More Tools Register for FREE

Pin to quick picksTekCapital Regulatory News (TEK)

Share Price Information for TekCapital (TEK)

Share Price is delayed by 15 minutes
Get Live Data
5.80    -0.10 (-1.69%)
Bid:
5.70
Ask:
5.90
Spread: 0.20 (3.509%)
Market Cap: £14.92m
TEK Live PriceLast checked at - London Stock Exchange

Intraday TekCapital Share Chart

Contract Win

10 Jun 2025 07:00

RNS Number : 0211M
GenIP PLC
10 June 2025
 

 

 

10 June 2025 

 

GenIP Plc

("GenIP" or the "Company")

 

Contract Win

 

GenIP Plc, a technology business providing Generative Artificial Intelligence (GenAI) services to help research organisations and corporations commercialise their innovations, is pleased to announce its expansion into the Republic of Chile through an engagement for 30 analytical assessment orders from a leading research institution.

 

This order increases the total value of Invention Evaluator orders received by GenIP since its IPO in October 2024 to over $850,000[1].

 

 

Melissa Cruz, CEO of GenIP, commented:

 

"I am delighted to announce another new international contract with a leading research university, marking GenIP's first entry into the Chilean market. The institution has purchased 30 Invention Evaluator assessments, to support technology commercialisation decisions across its research portfolio. This milestone strengthens GenIP's growing footprint in Latin America and underscores global demand for its GenAI-enabled services.

 

"GenIP's global expansion is underpinned by a healthy balance sheet that allows the Company to capitalise on opportunities as they arise. As outlined in our audited results, the reported Operating Loss of $888,545 included $358,924 of share-based payments relating to the IPO that are not expected to recur. Customers typically pay in advance for Invention Evaluator report orders, providing the Company with operating cash flow and future revenue visibility, with revenue recognised upon completion and delivery of the report to the client. These factors help maintain the Company's strong financial position."

 

 

 

For further information regarding GenIP, please visit https://genip.ai/, or contact:

 

GenIP Plc

Melissa Cruz, CEO 

Via Redchurch Communications

Beaumont Cornish Limited (Nominated Adviser)

Roland Cornish / Asia Szusciak / Andrew Price

 

 

Tel: +44 (0) 20 7628 3396

 

Novum Securities Limited (Broker) 

Jon Belliss

Tel: +44 (0)20 7399 9425

JBelliss@novumsecurities.com

 

 

Redchurch Communications (Financial PR)

John Casey

 

 

genip@weareredchurch.com

 

The information communicated within this announcement is deemed to constitute inside information as stipulated under the Market Abuse Regulations (EU) No 596/2014 which is part of UK law by virtue of the European Union (Withdrawal) Act 2018.

 

Beaumont Cornish Limited ("Beaumont Cornish") is the Company's Nominated Adviser and is authorised and regulated by the FCA. Beaumont Cornish's responsibilities as the Company's Nominated Adviser, including a responsibility to advise and guide the Company on its responsibilities under the AIM Rules for Companies and AIM Rules for Nominated Advisers, are owed solely to the London Stock Exchange. Beaumont Cornish is not acting for and will not be responsible to any other persons for providing protections afforded to customers of Beaumont Cornish nor for advising them in relation to the proposed arrangements described in this announcement or any matter referred to in it.

 

Notes to Editors

 

About GenIP

 

GenIP provides generative artificial intelligence (GenAI) analytic services to help companies, research institutions and venture funds assess and commercialise new discoveries. GenIP combines expert human technical review with GenAI algorithms to provide insightful and verified services.

 

GenIP provides two complementary platform-based services:

1. Invention Evaluator: Provides bespoke research reports that assess the market potential of new technological innovations and discoveries using AI-driven proprietary software; and

 

2. Vortechs: which is an executive recruitment platform that through advanced machine learning algorithms and natural language processing technologies assists in matching technology organisations with experienced executives skilled in technology commercialisation.

 

The Company believes that its integrated GenAI service offerings will help organisations to evaluate and commercialise their technological innovations. 

Company Strategy

GenIP's goal is to be a leading Generative AI analytic services company. To achieve this, the Company has established three strategic pillars:

 

Organically grow Invention Evaluator and Vortechs' revenue through institutional and corporate connections as well as increase client pipeline through marketing, advertising and social media spend.

Expand the Generative AI service offerings within Invention Evaluator and Vortechs' to reach new customers and improve margins.

Bolt-on acquisitions of additional Generative AI services that are helpful to our clients and have demonstrated initial market traction. 

 

 

Forward looking statements

 

Certain statements contained in this announcement constitute forward-looking statements. When used in this announcement, the words "may", "would", "could", "will", "intend", "plan", "anticipate", "believe", "seek", "propose", "estimate", "expect", and similar expressions, as they relate to the Company, are intended to identify forward-looking statements. These statements include, but are not limited to, statements regarding intentions, beliefs or current expectations concerning, among other things, the Company's results of operations, financial position, liquidity, prospects, growth, strategies and expectations of the industry in which the Company operates.

 

Such statements reflect the Company's current views with respect to future events and are subject to certain risks, uncertainties and assumptions. Many factors could cause the Company's actual results, performance or achievements to materially differ from those described in this announcement Should one or more of these risks or uncertainties materialise, or should assumptions underlying forward-looking statements prove incorrect, actual results may differ materially from those described in this announcement as "intended", "planned", "anticipated", "believed", "proposed", "estimated" or "expected".

 

For the avoidance of doubt, the contents of the Company's website and any hyperlinks accessible from the Company's website are not incorporated by reference into, and do not form part of, this announcement and investors should not rely on them.

-ENDS-


[1] Orders are treated as pre-payments with revenue recognised upon report production by GenIP and delivery to the client. Typically, pre-payments are utilised approximately 50% within the first 12 months and the balance over the following 12-18 months.

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
CNTUKRRRVRUNRAR
Date   Source Headline
20th Apr 201612:53 pmRNSHolding(s) in Company
13th Apr 20167:00 amRNSAcquisition of Medical Devices
14th Mar 20167:00 amRNSNew Technology License
12th Feb 20167:00 amRNSDirectorate Change
12th Jan 20167:00 amRNSTekcapital Chairman announced as award finalist
4th Jan 20163:06 pmRNSHolding(s) in Company
24th Dec 20157:00 amRNSAcquisition of Energy Harvesting Technology
22nd Dec 201512:52 pmRNSHolding(s) in Company
30th Nov 20155:30 pmRNSTotal Voting Rights
24th Nov 20152:14 pmRNSExercise of warrants and total voting rights
23rd Nov 20157:00 amRNSPatent Update for Crackle-baked(R) Technology
13th Nov 20159:15 amRNSHolding(s) in Company
10th Nov 20157:00 amRNSDirectorate Change
9th Nov 20157:00 amRNSNew Patent Application
9th Oct 20157:00 amRNSHolding(s) in Company
28th Aug 20155:00 pmRNSTotal Voting Rights
20th Aug 20157:00 amRNSHalf Yearly Report
14th Aug 20157:00 amRNSAcquisition of air conditioning efficiency patents
29th Jun 20157:00 amRNSAcquisition of energy harvesting technologies
22nd Jun 20154:27 pmRNSHolding(s) in Company
12th Jun 201511:52 amRNSResult of General Meeting
8th Jun 20157:00 amRNSGrant of Share Options
29th May 20156:15 pmRNSHolding(s) in Company
29th May 20156:15 pmRNSTotal Voting Rights
29th May 20151:13 pmRNSResult of AGM
21st May 201512:52 pmRNSFinal Results
14th May 20154:07 pmRNSHolding(s) in Company
13th May 20157:00 amRNSHolding(s) in Company
12th May 20152:00 pmRNSHolding(s) in Company
12th May 20157:00 amRNSHolding in Company and Directorate Change
6th May 20152:46 pmRNSNotice of AGM
6th May 20157:01 amRNSPlacing
1st May 20157:00 amRNSTotal Voting Rights
14th Apr 20157:00 amRNSTechnology Acquisition
10th Apr 20157:01 amRNSTechnology Acquisition
10th Apr 20157:00 amRNSAppointment of Nominated Adviser and Joint Broker
7th Apr 20153:08 pmRNSAIM Disclosure
2nd Apr 20157:00 amRNSTechnology Acquisition
24th Mar 20157:00 amRNSStrategic Alliance
11th Feb 20157:00 amRNSStrategic Alliance
6th Feb 20157:00 amRNSIssue of Shares
27th Jan 20157:01 amRNSTechnology acquisition
20th Jan 20157:00 amRNSNew Client Wins
15th Jan 20157:00 amRNSNew Client Wins
2nd Dec 20147:00 amRNSStrategic Alliance
21st Nov 20147:00 amRNSTrading Update
28th Aug 20147:00 amRNSUnaudited Interim Results
23rd Jul 20142:51 pmRNSAcquisition of InventionEvaluator.com
23rd May 20147:00 amRNSTeam Expansion & Opening Of New Offices
9th May 20149:54 amRNSHolding(s) in Company

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.